Patient-friendly, non-technical summary of research papers

August 2026 Research Update

This report covers research on Sanfilippo syndrome published in PubMed in August 2026. For other months, see all research updates.

Last update: September 1, 2026

At a glance

Diagnosis by exome

Whole-exome sequencing helped diagnose when enzyme testing was unavailable.

Subtype labels

Genetic results identified MPS IIIA and MPS IIIC subtypes.

Brain imaging findings

Brain scans showed changes consistent with ongoing brain involvement.

Genetic-first diagnosis

This month highlighted using broad genetic testing to diagnose and subtype Sanfilippo syndrome when standard enzyme confirmation is not available. The reports linked genetic findings with real-world symptoms, but some usual confirmation steps were missing.

Overview

This month focused on diagnosis and real-world recognition of Sanfilippo syndrome in a setting with limited standard testing.

One report described two adolescents in Yucatan, Mexico who were diagnosed using broad genetic testing, also called whole-exome sequencing. This shows a practical path to reaching a diagnosis when enzyme-based confirmation is not available. It also helps label the specific subtype, such as MPS IIIA or MPS IIIC.

The report included different genetic findings in each adolescent. One adolescent was classified as MPS IIIC with a known disease-causing change in the HGSNAT gene. The other was classified as MPS IIIA with two newly reported changes in the SGSH gene that were described as likely disease-causing.

The report also connected the genetic results to everyday impact. Brain imaging in both adolescents showed signs consistent with progressive brain involvement, including brain volume loss. The descriptions included loss of skills and high caregiver dependence, with issues like sleep and behavior symptoms, seizures in one case, and feeding support in the other.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Sanfilippo syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month added a small but important real-world example of how Sanfilippo syndrome can be identified when standard lab tests are not available. In two adolescents from Yucatan, Mexico with suspected lysosomal disease, whole-exome sequencing (a broad genetic test) was used as the main tool to confirm Sanfilippo syndrome and define the specific subtype. This supports the idea that access to genetic testing can make diagnosis possible even in settings with limited enzyme-based confirmation, and it raises the possibility that some people in the region may be missed or diagnosed late.

The report identified two different Sanfilippo subtypes, each linked to a different gene. One patient had MPS IIIC with a known disease-causing change in HGSNAT, while the other had MPS IIIA with two newly reported (novel) gene changes in SGSH that were considered likely disease-causing. Because parental testing and enzyme testing were not available, some details such as confirming how the gene changes were inherited could not be fully checked, but the genetic findings were still used to support the diagnoses.

The study also described signs of ongoing brain involvement on imaging, alongside progressive day-to-day difficulties typical of Sanfilippo syndrome. Both adolescents had neuroimaging changes such as subcortical brain atrophy, and the report described progressive loss of skills and high care needs, including problems such as sleep disturbance, behavior symptoms, seizures in one case, and feeding support in the other. This helps connect the genetic findings to the lived reality of the condition, even though it does not test a treatment or predict outcomes for others.

For patients and caregivers, this month mainly adds understanding about diagnosis rather than treatment. It shows that broad genetic testing may help reach a Sanfilippo diagnosis and subtype label (like MPS IIIA or IIIC) in places where enzyme testing is hard to access, and it also documents that these subtypes are being recognized in Mexico. What remains uncertain is how often this approach will work without other confirmation in different settings, and how common these specific gene changes are in the wider community, since this was only two people.

Limitations

The evidence came from only two individuals in one report.
Enzyme testing was not available to confirm the diagnoses.
Parental testing was not available, so inheritance details could not be fully checked.
The newly reported SGSH gene changes are not yet known to be common in the wider community.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.